Last reviewed · How we verify

Period 1 - Day 1: PF-04965842 administered

Pfizer · Phase 1 active Small molecule

Period 1 - Day 1: PF-04965842 administered is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development. Also known as: Single administration of PF-04965842 in Period 1..

At a glance

Generic namePeriod 1 - Day 1: PF-04965842 administered
Also known asSingle administration of PF-04965842 in Period 1.
SponsorPfizer
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Period 1 - Day 1: PF-04965842 administered

What is Period 1 - Day 1: PF-04965842 administered?

Period 1 - Day 1: PF-04965842 administered is a Small molecule drug developed by Pfizer.

Who makes Period 1 - Day 1: PF-04965842 administered?

Period 1 - Day 1: PF-04965842 administered is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is Period 1 - Day 1: PF-04965842 administered also known as anything else?

Period 1 - Day 1: PF-04965842 administered is also known as Single administration of PF-04965842 in Period 1..

What development phase is Period 1 - Day 1: PF-04965842 administered in?

Period 1 - Day 1: PF-04965842 administered is in Phase 1.

Related